Stoke Therapeutics is a late-stage clinical biotechnology company developing antisense oligonucleotides (ASOs) to treat severe genetic diseases by upregulating protein expression. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform, the company focuses on haploinsufficiency disorders, particularly those affecting the central nervous system and the eye. Its lead candidate, zorevunersen (STK-001), is in a global Phase 3 trial for Dravet syndrome, a severe genetic epilepsy, with a collaboration with Biogen for development and commercialization outside the United States, Canada, and Mexico. The company is also advancing STK-002 for autosomal dominant optic atrophy (ADOA) and maintains preclinical programs across other disease areas. Founded in 2014 by co-founders Adrian Krainer and Isabel Aznarez, Stoke Therapeutics targets the underlying genetic causes of these conditions to restore physiological protein levels.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage stoketherapeutics.com
Sector Healthcare IR page investor.stoketherapeutics.com
Tags
antisense oligonucleotides, rna therapeutics, dravet syndrome, genetic epilepsy, autosomal dominant optic atrophy, haploinsufficiency, central nervous system, rare diseases, protein upregulation, TANGO, zorevunersen, STK-001, STK-002, EMPEROR, MONARCH, ADMIRAL, Biogen
Press page —

Metrics

Valuation  
Market cap $ 1.73B
Market cap (USD) $ 1.73B
P/E -7.08
PEG —
P/BV 4.91
P/S 61.31
P/OCF -8.22
P/FCF -8.02
Dividend yield —
Turnover / mcap —
Returns  
ROE -2.4%
ROI -2.6%
ROIC -5.7%
Profit margin -3.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 27
Quality score -23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 184.42M 36.555M 8.78M 12.405M — — — —
Net profit -6.885M -88.981M -104.699M -101.067M -85.805M -52.243M -32.325M -12.521M
Free cash flow 44.915M -87.054M -82.683M -35.828M -68.107M -43.271M -32.69M -11.899M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 31.74 11.03 5.26 9.23 23.99 61.93 28.32 —
Price performance 12m 1.88 1.1 -0.43 -0.62 -0.61 1.19 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — — 1.67M 5.94M
↳ YoY growth +255.9%
Lease liabilities (USD) — — 1.15M 5.04M 5.08M 6.84M 4.77M 4.15M
Cash and deposits (USD) 105M 222M 287M 145M 114M 191M 128M 84.2M
Right-of-use assets (USD) — — 1.12M 4.94M 4.75M 6.61M 4.35M 3.1M
Cash flow detail
Operating cash flow (USD) -11M -31.1M -42.2M -66.9M -31.9M -81.1M -86.9M 45.6M
Purchases of property, plant and equipment (USD) -935,000 -1.64M -1.05M -1.2M -3.96M -1.62M -203,000 -670,000
Change in receivables (cash effect) (USD) — — — — — — -50,000 -4.27M
Change in payables (cash effect) (USD) 1.74M 891,000 5.2M 2.9M -3.53M — — —
Income taxes paid (cash effect) (USD) — — — — — — — -573,000
Share-based compensation (USD) 240,000 1.92M 5.77M 16.5M 22.9M 25.3M 27.5M 32.2M
Operating cash flow before change in receivables (USD) — — — — — — -86.8M 49.9M
Free cash flow (OCF - PPE - intangibles) (USD) -11.9M -32.7M -43.3M -68.1M -35.8M -82.7M -87.1M 44.9M
Income detail
Research and development expense (USD) 8.37M 23.8M 32.2M 54.2M 77.8M 82.2M 89.1M 138M
↳ 5y CAGR +57.9% +30.3% +33.8%
Total comprehensive income (USD) — — -52.2M -86M -102M -104M -89.1M -6.19M
Comprehensive income to owners (USD) — — -52.2M -86M -102M -104M -89.1M -6.19M
Reported Mar 23, 2020 Mar 23, 2020 Mar 10, 2022 Mar 10, 2022 Mar 6, 2023 Mar 25, 2024 Mar 16, 2026 Mar 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

–Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome: ~110 patients through Week 28 primary endpoint, ~20 patients through Week 52 and all continuing into open-label treatment period; data readout anticipated in Q3 2027 followed by the planned U.S. NDA submission in H2 2027–

–Successful FDA meeting to align on U.S. NDA submission: Changes in cognition and behavior, a key secondary endpoint in EMPEROR, will be analyzed using a multicomponent assessment of four Vineland-3 subdomains–

–STK-002, an investigational medicine for ADOA: Dose escalation in the Phase 1 OSPREY study continues with dosing of third cohort underway; initial safety and efficacy data anticipated in H1 2027–

–$358.8M in cash, cash equivalents and marketable securities as of September 30, 2026 expected to fund operations into early 2028–

–Webcast and conference call for analysts and investors at 4:30PM Eastern Time today–

BEDFORD, Mass., October 29, 2026 – Stoke Therapeutics, Inc.

October 22, 2026

PDF Version

BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 22, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that management will host a webcast and conference call for analysts and investors on Thursday, October 29, 2026, at 4:30 p.m. ET, to discuss third quarter 2026 business and financial updates.

The webcast will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/. Research analysts who plan to join the call and participate in the Q&A session may register here to receive the dial-in details and a unique PIN. All other participants are invited to access the listen-only webcast by clicking here. An archived replay of the webcast will be available for at least 90 days following the event.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ and follow us on LinkedIn.

About Zorevunersen

Zorevunersen is an investigational antisense oligonucleotide that is designed to treat the underlying cause of Dravet syndrome by increasing functional NaV1.1 protein production in brain cells from the unaffected (wild-type) copy of the SCN1A gene. This highly differentiated mechanism of action aims to reduce seizure frequency beyond what has been achieved with anti-seizure medicines and to improve neurodevelopment, cognition and behavior. Zorevunersen has demonstrated the potential for disease modification and has been granted orphan drug designation by the FDA and the EMA. The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function in the SCN1A gene, and China’s Center for Drug Evaluation has granted zorevunersen Breakthrough Therapy Designation. Stoke has a strategic collaboration with Biogen (Nasdaq: BIIB) to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights. Zorevunersen is currently in clinical development, and its safety and efficacy have not been evaluated by any regulatory authority.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261022784889/en/

**Stoke Media & Investor Contacts:**Susan Willson Vice President, Corporate Communications [email protected] 415-509-8202

Investor Relations [email protected]

Source: Stoke Therapeutics, Inc.

Print Page

Email Alerts

Contact IR

Investor FAQs

Company Logo

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below. The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. We also use third-party cookies that help us analyze how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent. You can choose to enable or disable some or all of these cookies but disabling some of them may affect your browsing experience.

October 16, 2026

PDF Version

BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 16, 2026-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on October 15, 2026, it granted stock options to purchase shares of common stock to Stephen Aschettino, the Company’s newly-appointed Senior Vice President, Chief Information Officer, and seventeen other new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The company granted Mr. Aschettino stock options to purchase 70,000 shares of common stock. The stock options that were granted have an exercise price of $24.61 per share, which is equal to the closing price of Stoke’s common stock on October 15, 2026. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying each employee’s option over the following 36 months, subject to the employee’s continued employment with Stoke on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.

In addition, the company granted stock options to purchase an aggregate of 175,920 shares of common stock to seventeen new employees. The stock options that were granted have an exercise price of $24.61 per share, which is equal to the closing price of Stoke’s common stock on October 15, 2026. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying each employee’s option over the following 36 months, subject to the employee’s continued employment with Stoke on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.

About Stoke TherapeuticsStoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261016401922/en/

Stoke Media & Investor Contacts: Susan Willson Vice President, Corporate Communications [email protected]

415-509-8202 Investor Relations [email protected] 508-642-6485

Source: Stoke Therapeutics, Inc.

Print Page

Email Alerts

Contact IR

Investor FAQs

Company Logo

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below. The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. We also use third-party cookies that help us analyze how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent. You can choose to enable or disable some or all of these cookies but disabling some of them may affect your browsing experience.

Prompts

Stoke Therapeutics, Inc. (ticker STOK), listed in United States.

Company History

Date Change Detail
Nov 2, 2018 Renamed ASOthera Pharmaceuticals, Inc. → STOKE THERAPEUTICS, INC.

ETFs Holding Stoke Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
HELX 1.33% 11,349 $ 371.339K Jun 30, 2026
FMED 0.95% 15,670 $ 488.904K Aug 31, 2026
HRTS 0.56% 9,917 $ 309.41K Aug 31, 2026
TMED 0.31% 2,167 $ 70.904K Jun 30, 2026
FFSM 0.17% 86,608 $ 2.5M Jul 31, 2026
SEIS 0.17% 29,412 $ 962.361K Jun 30, 2026
FSEG 0.16% 278 $ 9,096.16 Jun 30, 2026
ESSC 0.10% 1,208 $ 34.863K Jul 31, 2026
PSC 0.09% 64,927 $ 2.124M Jun 30, 2026
FSML 0.09% 3,325 $ 108.794K Jun 30, 2026
TCAF 0.07% 276,416 $ 7.361M Nov 17, 2026
TMSL 0.06% 50,351 $ 1.647M Jun 30, 2026
RESM 0.05% 60 $ 1,963.20 Jun 30, 2026
VFMO 0.04% 25,172 $ 785.366K Aug 31, 2026
DFAS 0.02% 276,104 $ 7.234M Nov 12, 2026
MSSM 0.01% 2,760 $ 86.112K Aug 31, 2026
DFAC 0.00% 141,236 $ 3.7M Nov 12, 2026
DFSU 0.00% 2,333 $ 61.125K Nov 12, 2026
DFAU 0.00% 7,377 $ 193.277K Nov 12, 2026
DFUS 0.00% 10,631 $ 278.532K Nov 12, 2026
DCOR 0.00% 18,183 $ 476.395K Nov 12, 2026
DFUV 0.00% 341 $ 8,934.20 Nov 12, 2026
NTRL short 0.00% -5,806 $ 0.00 Nov 16, 2026